Edition:
United Kingdom

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

18.44USD
19 Sep 2018
Change (% chg)

$0.93 (+5.31%)
Prev Close
$17.51
Open
$17.46
Day's High
$18.64
Day's Low
$17.46
Volume
299,870
Avg. Vol
248,698
52-wk High
$41.14
52-wk Low
$16.71

Latest Key Developments (Source: Significant Developments)

Radius Health Says CHMP Communicated Negative Trend Vote For Co's Marketing Application For Abaloparatide-Sc
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Radius Health Inc ::RADIUS HEALTH PROVIDES UPDATE ON APPEAL OF CHMP OPINION FOR ABALOPARATIDE-SC.RADIUS HEALTH - CHMP, EMA HAS COMMUNICATED A NEGATIVE TREND VOTE FOR CO'S MARKETING AUTHORIZATION APPLICATION FOR ABALOPARATIDE-SC.  Full Article

Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Radius Health Inc ::RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE.RADIUS HEALTH-EXPECTS COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE TO ISSUE AN OPINION REGARDING MARKETING AUTHORISATION APPLICATION DURING H1 2018.  Full Article

Radius Health reports Q3 loss per share $1.31
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Radius Health Inc :Radius Health Inc reports third quarter 2017 financial and operating results and provides business update.Q3 loss per share $1.31.Q3 earnings per share view $-1.26 -- Thomson Reuters I/B/E/S.Radius Health Inc - ‍expects to submit a labeling supplement to FDA in connection with activextend results by end of 2017​.Radius health inc - ‍expects to reduce size of board from 10 to 9 members​.Radius Health Inc - believe have sufficient capital to fund development plans, U.S. Commercial and other operational activities for not less than 12 months​.  Full Article

Radius Health receives FDA fast track designation for elacestrant
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Radius Health Inc :Radius health receives fda fast track designation for elacestrant (rad1901).Radius health - ‍plans to initiate phase 2 clinical study of elacestrant as a third-line therapy for women with er+ and her2- breast cancer early in 2018​.Radius health inc - ‍expect to enroll first patient in phase 2 study in early 2018​.  Full Article

BRIEF-Radius Health Reports Q1 Loss Per Share Of $1.37

* RADIUS HEALTH REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE